PMID- 18541194
OWN - NLM
STAT- MEDLINE
DCOM- 20080804
LR  - 20211020
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 14
IP  - 7
DP  - 2008 Jul
TI  - Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic 
      transplant correlate with graft-versus-host disease severity and overall survival 
      in pediatric patients.
PG  - 759-65
LID - 10.1016/j.bbmt.2008.04.002 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is known to play a role in the 
      pathogenesis of graft-versus-host disease (GVHD), a cause of significant 
      morbidity and treatment-related mortality (TRM) after allogeneic hematopoietic 
      stem cell transplantation (HCT). We measured the concentration of TNF-Receptor-1 
      (TNFR1) in the plasma of HCT recipients as a surrogate marker for TNF-alpha both 
      prior to transplant and at day 7 in 82 children who underwent a myeloablative 
      allogeneic HCT at the University of Michigan between 2000 and 2005. GVHD grade 
      II-IV developed in 39% of patients at a median of 20 days after HCT. Increases in 
      TNFR1 level at day 7 post-HCT, expressed as ratios compared to pretransplant 
      baseline, correlated with the severity of GVHD (P = .02). In addition, day 7 
      TNFR1 ratios >2.5 baseline were associated with inferior 1-year overall survival 
      (OS 51% versus 74%, P = .04). As an individual biomarker, TNFR1 lacks sufficient 
      precision to be used as a predictor for the development of GVHD. However, 
      increases in the concentration of TNFR1, which are detectable up to 2 weeks in 
      advance of clinical manifestations of GVHD, correlate with survival in pediatric 
      HCT patients.
FAU - Kitko, Carrie L
AU  - Kitko CL
AD  - Department of Pediatrics, University of Michigan Medical School, Ann Arbor, 
      Michigan, USA. ckitko@med.umich.edu
FAU - Paczesny, Sophie
AU  - Paczesny S
FAU - Yanik, Gregory
AU  - Yanik G
FAU - Braun, Thomas
AU  - Braun T
FAU - Jones, Dawn
AU  - Jones D
FAU - Whitfield, Joel
AU  - Whitfield J
FAU - Choi, Sung W
AU  - Choi SW
FAU - Hutchinson, Raymond J
AU  - Hutchinson RJ
FAU - Ferrara, James L M
AU  - Ferrara JL
FAU - Levine, John E
AU  - Levine JE
LA  - eng
GR  - K12 HD028820-15/HD/NICHD NIH HHS/United States
GR  - K12 HD028820/HD/NICHD NIH HHS/United States
GR  - K12HD028820-15/HD/NICHD NIH HHS/United States
GR  - P01 CA039542-20/CA/NCI NIH HHS/United States
GR  - P01 CA039542/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
SB  - IM
MH  - Adolescent
MH  - Biomarkers/blood
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Graft vs Host Disease/*blood
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Infant
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous
PMC - PMC2577819
MID - NIHMS55710
COIS- Conflict of interest statement: The authors declare no competing financial 
      interests.
EDAT- 2008/06/11 09:00
MHDA- 2008/08/05 09:00
PMCR- 2009/07/01
CRDT- 2008/06/11 09:00
PHST- 2007/11/29 00:00 [received]
PHST- 2008/04/09 00:00 [accepted]
PHST- 2008/06/11 09:00 [pubmed]
PHST- 2008/08/05 09:00 [medline]
PHST- 2008/06/11 09:00 [entrez]
PHST- 2009/07/01 00:00 [pmc-release]
AID - S1083-8791(08)00148-1 [pii]
AID - 10.1016/j.bbmt.2008.04.002 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2008 Jul;14(7):759-65. doi: 
      10.1016/j.bbmt.2008.04.002.